Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...
The Pharma Letter1d
Neurocrine touts further positive trial results for Ingrezza
US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...
JetBlue adds regular supply of sustainable aviation fuel at this East Coast hub
JetBlue and its fuel partners are celebrating the first-ever regular supply of sustainable aviation fuel (SAF) at New York’s ...
Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...
Xbox's new gaming Copilot AI would have been better with Kinect — there, I said it
Xbox's new Copilot for Gaming would be a much better idea in a world where we still had a Kinect we could talk to it with.
I would use Xbox's new gaming Copilot AI, except it's impossible to use it how it makes the most sense
Xbox's new Copilot for Gaming would be a much better idea in a world where we still had a Kinect we could talk to it with.
Neurocrine presents new KINECT-HD data
Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...